EffRx announced that the FDA has granted orphan drug designation to EX404 for the treatment of pediatric polycystic ovary syndrome (PCOS).
EX404 is a proprietary metformin-based drug candidate. EffRx plans to initiate the first EX404 clinical trial this fall. PCOS, also known as Stein-Leventhal Syndrome, is a heterogeneous disorder of chronic anovulation and hyperandrogenism that may result from a hormonal imbalance created by a combination of increased androgens and/or insulin.
For more information visit EffRx.com.